@ARTICLE{
author={Murrell Dedee F,Paller Amy S,Bodemer Christine,Browning John,Nikolic Milos MI,Barth Jay A,Lagast Hjalmar,Krusinska Eva,Reha Allen},
year={2020},
title={Wound closure in epidermolysis bullosa: data from the vehicle arm of the phase 3 ESSENCE Study},
journal={ORPHANET JOURNAL OF RARE DISEASES},
volume={15},
number={1},
pages={-},
document_type={Article},
} 

@ARTICLE{
author={Paller Amy S,Browning John,Nikolic Milos MI,Bodemer Christine,Murrell Dedee F,Lenon Willistine,Krusinska Eva,Reha Allen,Lagast Hjalmar,Barth Jay A},
year={2020},
title={Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study)},
journal={ORPHANET JOURNAL OF RARE DISEASES},
volume={15},
number={1},
pages={-},
document_type={Article},
} 

@ARTICLE{
author={Paller Amy S,Browning John,Nikolic Milos MI,Bodemer Christine,Krusinska Eva,Reha Allen,Lagast Hjalmar,Barth Jay A},
year={2018},
title={Results from the phase 3, double-blind, vehicle-controlled ESSENCE trial of the topical investigational drug SD-101 in epidermolysis bullosa},
journal={JOURNAL OF INVESTIGATIVE DERMATOLOGY},
volume={138},
number={5},
pages={S100-S100},
document_type={Meeting Abstract},
}